99mTc(CO) 3-Nitrilotriacetic Acid: A new renal radiopharmaceutical showing pharmacokinetic properties in rats comparable to those of 131I-OIH

Journal of Nuclear Medicine

Volumn 50, Issue 3, 2009, Pages 454-460

  Lipowska, Malgorzata ^a   Marzilli, Luigi G ^b   Taylor, Andrew T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

131l ortho iodohippurate ( 131l oih); 99mtc(co) 3(nta); 99mtc Mercaptoacetyltriglycine ( 99mtco mag3); 99mtc tricarbonyl; Renal radiopharmaceuticals

Indexed keywords

IODOHIPPURATE SODIUM I 131; MERTIATIDE TC 99M; NITRILOTRIACETIC ACID; TECHNETIUM 99M; TRICARBONYLNITRILOTRIACETIC ACID TC 99M; UNCLASSIFIED DRUG; IODOHIPPURIC ACID; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M TRICARBONYL NITRILOTRIACETIC ACID; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG UPTAKE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; IODOHIPPURIC ACID; KIDNEY; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 62449326839     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.058768     Document Type: Article

References (28)

1. Hermann HI, Lange D. Eisenhul M, Schenck P, zum Winkel K. Radiation dose and labeling of hippuran, Contrib Nephrol. 1978;11:100-104.
2. Taylor A, Eshima D, Fritzberg AR. Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986:27:795-803.
3. Eshima D. Taylor A, Fritzberg AR. Kasina S, Hansen L, Sorenson JF. Animal evaluation of technetium-99m triamide mercaptide complexes as potential renal imaging agents. J Nucl Med. 1987:28:1180-1186.
4. 99mTc renal tubular function agent. Semin Nucl Med. 1992;22:61-73.
5. Hansen L, Marzilli LG, Eshima D, Malveaux E, Folks R, Taylor A, Evaluation of technetium -99m-triamide-mercaptide complexes designed to identify properties favoring renal tubular transport. J Nucl Med. 1994;35:1198-1205.
6. Taylor A, Hansen L, Eshima D, et al. Comparison of technetium-99m-LE-EC isomers in rats and humans. J Nucl Med. 1997;38:821-826.
7. 99mTc-EC. J Nucl Med. 2004;45:885-891.
8. 2) radiopharmaceutical analogues as revealed by a novel dominant tautomer in the solid state. Inorg Chem. 1999;38:5351-5358.
9. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2002:29:1529-1542.
10. 4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987-7988.
11. +. J Am Chem Soc. 2001;123:3135-3136.
12. 3(LAN), as a new renal radiopharmaceutical in humans. J Nucl Med. 2006;47:1032-1040.
13. 99mTc imaging agents: structural characterization and solution behavior of complexes with thioether-bearing amino acids as tridentate ligands. Inorg Chem. 2005;44:5437-5446.
14. 3 analogues. Nucl Med Biol. 2007;34:709-716.
15. 3] complex. Tetrahedron Lett. 2004;45:2531-2534.
16. 131I-labeled hippuran. Int J Appl Radial Isot. 1964;15:95.
17. Hosick TA, Watts EC, Meschan I. The removal and control of iodide-131 contamination in sodium o-iodo-131 hippurate. J Nucl Med. 1966;7:643-646.
18. Marti N, Spingler B, Breher F, Schibli R. Comparative studies of substitution reactions of rhenium(I) dicarbonyl-nitrosyl and tricarbonyl complexes in aqueous media. Inorg Chem. 2005;44:6082-6091.
19. 2+. Tetrahedron Lett. 2004;45:4089-4092.
20. Chatterjee M, Banerjee S. Functionalization of hydroxy compounds with nitrilotriacetic acid for technetium-99m chelation: excretory properties of the radiolabeled chelates. Int J Rod Appl lnstrum B. 1991;18:263-274.
21. Havránek F, Bumbálová A. Krenek P, Komová M, Beláková M. Development of new radiopharmaceuticals: technetium aminopolycarboxylate complexes. Phar-mazie. 1994;49:369-370.
22. Vrana V. Kleisner I. Preparation and characterization of technelium-99m labeled chelates for use in nuclear medicine. Radioisotopy. 1984;25:621-639.
23. 3(ENDAC) analog [abstract]. J Nucl Med. 2001;42(suppl):259P.
24. Budny JA, Arnold JD. Nitrilotriacelate (NTA): human metabolism and its importance in the total safety evaluation program. Toxicol Appl Pharmacol. 1973;25:48-53.
25. Health Canada. Environmental and Workplace Health. Nitrilotriacetic acid (NTA). 1990. Available at: http://www.hc-sc.gc.ca/ewh-semt/pubs/water-eau/ nitrilotriacetic-acid/index-eng.php. Accessed January 15, 2009.
26. World Health Organization. Nitrilotriacetic Acid in Drinking-Water. Guidelines for Drinking-Water Quality. Health Criteria and Other Supporting Information. Vol 2. 2nd ed. Geneva, Switzerland: World Health Organization; 1996.
27. 20) for Possible Carcinogenicity. NCI-CG-TR-6; DHEW Publication No. [NIH] 77-806. Bethesda, MD: National Cancer Institute; 1977.
28. Anderson RL, Bishop WE, Campbell RL. A review of the environmental and mammalian toxicology of nitrilotriacetic acid. Crit Rev Toxicol. 1985;15:1-102.